Norli Ellen Sauar, Brinkmann Gina Hetland, Kvien Tore Kristian, Bjørneboe Olav, Haugen Anne Julsrud, Nygaard Halvor, Thunem Cathrine, Lie Elisabeth, Mjaavatten Maria Dahl
Department of Rheumatology, Martina Hansens Hospital, Sandvika, Norway.
Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
RMD Open. 2017 Dec 22;3(2):e000573. doi: 10.1136/rmdopen-2017-000573. eCollection 2017.
To describe the diagnostic spectrum, arthritis persistency and clinical outcomes after 2 years in patients with inflammatory arthritis (IA) of less than 16 weeks' duration.
Data from the Norwegian Very Early Arthritis Clinic, a 2-year longitudinal observational study of adults with IA of ≤16 weeks' duration, were used. Exclusion criteria were arthritis due to crystal deposits, trauma, osteoarthritis and septic arthritis. In all patients who had any follow-up information (population A), clinical diagnoses and persistency of arthritis were described. For patients with 2-year follow-up (population B), we also studied other clinical outcomes (disease activity, pain, fatigue, functional disability and health-related quality of life).
In population A (n=1017) median (25th-75th percentile) duration of joint swelling was 35.0 (13.0-66.5) days, mean (SD) age 45.7 (14.8) years, 55.2% were females and 17.8% anticitrullinated protein antibodies positive. The most common final diagnoses were undifferentiated arthritis (UA) (41.7%), rheumatoid arthritis (RA) (24.1%) and reactive arthritis (18.1%). After 2 years, the arthritis had resolved in 59% of the patients. The remaining 41.0% had persistent disease defined by disease modifying antirheumatic drug (DMARD) use (32.1%) or persistent joint swelling without DMARD use (8.9%). In population B (n=669), all clinical outcomes improved significantly (P<0.001). Baseline joint pain and fatigue were similar across diagnoses.
Among 1017 patients with IA of ≤16 weeks' duration, UA was the most common diagnosis after 2 years, and less than one-fourth were diagnosed with RA. Arthritis resolved without DMARDs in the majority of the patients. All clinical parameters improved significantly over a 2-year course.
描述病程小于16周的炎症性关节炎(IA)患者的诊断谱、关节炎持续性及2年后的临床结局。
使用来自挪威极早期关节炎诊所的数据,这是一项对病程≤16周的成年IA患者进行的为期2年的纵向观察性研究。排除标准为因晶体沉积、创伤、骨关节炎和感染性关节炎导致的关节炎。在所有有任何随访信息的患者(A组)中,描述了临床诊断和关节炎的持续性。对于有2年随访的患者(B组),我们还研究了其他临床结局(疾病活动度、疼痛、疲劳、功能残疾和健康相关生活质量)。
在A组(n = 1017)中,关节肿胀的中位(第25 - 75百分位数)持续时间为35.0(13.0 - 66.5)天,平均(标准差)年龄45.7(14.8)岁,55.2%为女性,17.8%抗瓜氨酸化蛋白抗体阳性。最常见的最终诊断为未分化关节炎(UA)(41.7%)、类风湿关节炎(RA)(24.1%)和反应性关节炎(18.1%)。2年后,59%的患者关节炎已缓解。其余41.0%有持续性疾病,定义为使用改善病情抗风湿药物(DMARD)(32.1%)或未使用DMARD但关节持续肿胀(8.9%)。在B组(n = 669)中,所有临床结局均显著改善(P < 0.001)。各诊断之间的基线关节疼痛和疲劳情况相似。
在1017例病程≤16周的IA患者中,2年后最常见的诊断是UA,不到四分之一被诊断为RA。大多数患者未经DMARD治疗关节炎即缓解。所有临床参数在2年病程中均显著改善。